Zobrazeno 1 - 10
of 186
pro vyhledávání: '"Zheng Jian, Li"'
Autor:
Jianlin Xu, Matthew S. Rehmann, Mengmeng Xu, Shun Zheng, Charles Hill, Qin He, Michael C. Borys, Zheng Jian Li
Publikováno v:
Bioresources and Bioprocessing, Vol 7, Iss 1, Pp 1-16 (2020)
Abstract The goal of cell culture process intensification is to increase volumetric productivity, generally by increasing viable cell density (VCD), cell specific productivity or production bioreactor utilization in manufacturing. In our previous stu
Externí odkaz:
https://doaj.org/article/775ee38739c642cc9ba11407c734f826
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 18, Iss , Pp 3925-3935 (2020)
The hinge region of immunoglobulin G1 (IgG1) is used as a common linker for Fc-fusion therapeutic proteins. With the advances of high-resolution mass spectrometry and sample treatment strategies, unexpected O-linked glycosylation has been observed in
Externí odkaz:
https://doaj.org/article/95f781049f7d4746ad6e3b0abc5a0ef6
Autor:
Qin He, Jianlin Xu, Erik Vandermark, Jun Tian, Yueming Qian, Cynthia Chelius, Jongchan Lee, Michael C. Borys, Zheng Jian Li, Girish Pendse
Publikováno v:
Data in Brief, Vol 39, Iss , Pp 107491- (2021)
In this article, we present four sets of data from high-throughput screening (HTS) studies of different chemically defined media using an industrially relevant Chinese hamster ovary (CHO) cell line. While complex hydrolysate media was used in the ear
Externí odkaz:
https://doaj.org/article/0d07d6fd26134ab696ee55df8a686e52
Autor:
Steven W. Sowa, Yueming Qian, Kathryn L. Aron, Ping Xu, Erik Langsdorf, Bethanne Warrack, Nelly Aranibar, Gabi Tremml, Jianlin Xu, Duncan McVey, Michael Reily, Anurag Khetan, Michael C. Borys, Zheng Jian Li
Publikováno v:
Data in Brief, Vol 33, Iss , Pp 106591- (2020)
In this article, we provide four data sets for an industrial Chinese Hamster Ovary (CHO) cell line producing antibodies during a 14-day bioreactor run. This cell line was selected for further evaluation because of its significant titer loss as the ce
Externí odkaz:
https://doaj.org/article/542fd1b1e063445a8be941eb848a5c5d
Autor:
Qin He, Matthew S. Rehmann, Jun Tian, Jianlin Xu, Luzmary Sabino, Erik Vandermark, Ziev Basson, Iris Po, Kathleen Bierilo, Gabi Tremml, Giovanni Rizzi, Erik F. Langsdorf, Nan-Xin Qian, Michael C. Borys, Anurag Khetan, Zheng-Jian Li
Publikováno v:
Bioengineering, Vol 9, Iss 4, p 173 (2022)
Improving productivity to reduce the cost of biologics manufacturing and ensure that therapeutics can reach more patients remains a major challenge faced by the biopharmaceutical industry. Chinese hamster ovary (CHO) cell lines are commonly prepared
Externí odkaz:
https://doaj.org/article/9373598c5c5145a395f1797588ed2323
Autor:
Emily S. C. Rittershaus, Matthew S. Rehmann, Jianlin Xu, Qin He, Charles Hill, Jeffrey Swanberg, Michael C. Borys, Zheng-Jian Li, Anurag Khetan
Publikováno v:
Bioengineering, Vol 9, Iss 4, p 128 (2022)
Fed-batch process intensification with a significantly shorter culture duration or higher titer for monoclonal antibody (mAb) production by Chinese hamster ovary (CHO) cells can be achieved by implementing perfusion operation at the N-1 stage for bio
Externí odkaz:
https://doaj.org/article/24c0689bbc314e0d9abca2705b17017e
Autor:
Jianlin Xu, Xuankuo Xu, Chao Huang, James Angelo, Christopher L. Oliveira, Mengmeng Xu, Xia Xu, Deniz Temel, Julia Ding, Sanchayita Ghose, Michael C. Borys, Zheng Jian Li
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n =
Externí odkaz:
https://doaj.org/article/a3ee1083918640cc8d2da6b5af970e46
Autor:
Zhijun Tan, Vivekh Ehamparanathan, Tingwei Ren, Peifeng Tang, Laurel Hoffman, June Kuang, Peiran Liu, Chao Huang, Cheng Du, Li Tao, Letha Chemmalil, Angela Lewandowski, Sanchayita Ghose, Zheng Jian Li, Shijie Liu
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Disulfide bond reduction, which commonly occurs during monoclonal antibody (mAb) manufacturing processes, can result in a drug substance with high levels of low molecular weight (LMW) species that may fail release specifications because the drug’s
Externí odkaz:
https://doaj.org/article/18ea0b2eb9fc414ebf9fd1ddbcf039cb
Autor:
Zhiqiang Chen, Yueming Qian, Yuanli Song, Xuankuo Xu, Li Tao, Nesredin Mussa, Sanchayita Ghose, Zheng Jian Li
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Manufacturability of immunoglobulin G4 (IgG4) antibodies from the Chemistry, Manufacture, and Controls (CMC) perspective has received little attention during early drug discovery. Despite the success of protein engineering in improving antibody bioph
Externí odkaz:
https://doaj.org/article/4681f5b0243b4abfb5f83706253a71ac
Autor:
Peifeng Tang, Zhijun Tan, Vivekh Ehamparanathan, Tingwei Ren, Laurel Hoffman, Cheng Du, Yuanli Song, Li Tao, Angela Lewandowski, Sanchayita Ghose, Zheng Jian Li, Shijie Liu
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Disulfide bonds play a crucial role in folding and structural stabilization of monoclonal antibodies (mAbs). Disulfide bond reduction may happen during the mAb manufacturing process, resulting in low molecular weight species and possible failure to m
Externí odkaz:
https://doaj.org/article/c3dc9748a0654796b05a080bcd584973